Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

Self-assembled peptide-poloxamine nanoparticles enable in vitro and in vivo genome restoration for cystic fibrosis.

Guan S, Munder A, Hedtfeld S, Braubach P, Glage S, Zhang L, Lienenklaus S, Schultze A, Hasenpusch G, Garrels W, Stanke F, Miskey C, Johler SM, Kumar Y, Tümmler B, Rudolph C, Ivics Z, Rosenecker J.

Nat Nanotechnol. 2019 Jan 28. doi: 10.1038/s41565-018-0358-x. [Epub ahead of print]

PMID:
30692673
2.

Functional analysis of the p.[Arg74Trp;Val201Met;Asp1270Asn]/p.Phe508del CFTR mutation genotype in human native colon.

Schucht S, Minso R, Lex C, Reiss J, Stanke F, Tamm S, van Barneveld A, Tümmler B.

Mol Genet Genomic Med. 2019 Jan 1. doi: 10.1002/mgg3.526. [Epub ahead of print]

3.

An informative intragenic microsatellite marker suggests the IL-1 receptor as a genetic modifier in cystic fibrosis.

Stanke F, Hector A, Hedtfeld S, Hartl D, Griese M, Tümmler B, Mall MA.

Eur Respir J. 2017 Dec 28;50(6). pii: 1700426. doi: 10.1183/13993003.00426-2017. Print 2017 Dec. No abstract available.

PMID:
29284683
4.

Scavenger receptor class B member 1 (SCARB1) variants modulate hepatitis C virus replication cycle and viral load.

Westhaus S, Deest M, Nguyen ATX, Stanke F, Heckl D, Costa R, Schambach A, Manns MP, Berg T, Vondran FWR, Sarrazin C, Ciesek S, von Hahn T.

J Hepatol. 2017 Aug;67(2):237-245. doi: 10.1016/j.jhep.2017.03.020. Epub 2017 Mar 29.

PMID:
28363797
5.

Mechanism of allele specific assembly and disruption of master regulator transcription factor complexes of NF-KBp50, NF-KBp65 and HIF1a on a non-coding FAS SNP.

Awah CU, Tamm S, Hedtfeld S, Steinemann D, Tümmler B, Tsiavaliaris G, Stanke F.

Biochim Biophys Acta. 2016 Nov;1859(11):1411-1428. doi: 10.1016/j.bbagrm.2016.09.002. Epub 2016 Sep 9.

PMID:
27616356
6.

Classification of CFTR mutation classes.

Stanke F, Tümmler B.

Lancet Respir Med. 2016 Aug;4(8):e36. doi: 10.1016/S2213-2600(16)30147-3. Epub 2016 Jul 1. No abstract available.

PMID:
27377412
7.

Nasal potential difference of carriers of the W493R ENaC variant with non-cystic fibrosis bronchiectasis.

Rademacher J, Schulz A, Hedtfeld S, Stanke F, Ringshausen F, Welte T, Tümmler B.

Eur Respir J. 2016 Jan;47(1):322-4. doi: 10.1183/13993003.01128-2015. Epub 2015 Oct 9. No abstract available.

8.

The Contribution of the Airway Epithelial Cell to Host Defense.

Stanke F.

Mediators Inflamm. 2015;2015:463016. doi: 10.1155/2015/463016. Epub 2015 Jun 21. Review.

9.

The CF-modifying gene EHF promotes p.Phe508del-CFTR residual function by altering protein glycosylation and trafficking in epithelial cells.

Stanke F, van Barneveld A, Hedtfeld S, Wölfl S, Becker T, Tümmler B.

Eur J Hum Genet. 2014 May;22(5):660-6. doi: 10.1038/ejhg.2013.209. Epub 2013 Oct 9.

10.

Clinical and molecular characterization of the potential CF disease modifier syntaxin 1A.

von Kanel T, Stanke F, Weber M, Schaller A, Racine J, Kraemer R, Chanson M, Tümmler B, Gallati S.

Eur J Hum Genet. 2013 Dec;21(12):1462-6. doi: 10.1038/ejhg.2013.57. Epub 2013 Apr 10.

11.

CLCA4 variants determine the manifestation of the cystic fibrosis basic defect in the intestine.

Kolbe EW, Tamm S, Hedtfeld S, Becker T, Tümmler B, Stanke F.

Eur J Hum Genet. 2013 Jun;21(6):691-4. doi: 10.1038/ejhg.2012.234. Epub 2012 Oct 17.

12.

Initial interrogation, confirmation and fine mapping of modifying genes: STAT3, IL1B and IFNGR1 determine cystic fibrosis disease manifestation.

Labenski H, Hedtfeld S, Becker T, Tümmler B, Stanke F.

Eur J Hum Genet. 2011 Dec;19(12):1281-8. doi: 10.1038/ejhg.2011.129. Epub 2011 Jul 6.

13.

Anti-viral therapy in haemodialysed HCV patients: efficacy, tolerance and treatment strategy.

Deltenre P, Moreno C, Tran A, Ollivier I, Provôt F, Stanke F, Lazrek M, Castel H, Canva V, Louvet A, Colin M, Glowacki F, Dharancy S, Henrion J, Hazzan M, Noel C, Mathurin P.

Aliment Pharmacol Ther. 2011 Aug;34(4):454-61. doi: 10.1111/j.1365-2036.2011.04741.x. Epub 2011 Jun 20.

15.

Genes that determine immunology and inflammation modify the basic defect of impaired ion conductance in cystic fibrosis epithelia.

Stanke F, Becker T, Kumar V, Hedtfeld S, Becker C, Cuppens H, Tamm S, Yarden J, Laabs U, Siebert B, Fernandez L, Macek M Jr, Radojkovic D, Ballmann M, Greipel J, Cassiman JJ, Wienker TF, Tümmler B.

J Med Genet. 2011 Jan;48(1):24-31. doi: 10.1136/jmg.2010.080937. Epub 2010 Sep 12.

16.

Functional analysis of F508del CFTR in native human colon.

van Barneveld A, Stanke F, Tamm S, Siebert B, Brandes G, Derichs N, Ballmann M, Junge S, Tümmler B.

Biochim Biophys Acta. 2010 Nov;1802(11):1062-9. doi: 10.1016/j.bbadis.2010.08.001. Epub 2010 Aug 7.

17.

Head-out spirometry accurately monitors the course of Pseudomonas aeruginosa lung infection in mice.

Wölbeling F, Munder A, Stanke F, Tümmler B, Baumann U.

Respiration. 2010;80(4):340-6. doi: 10.1159/000319442. Epub 2010 Jul 21.

18.

Differential decay of parent-of-origin-specific genomic sharing in cystic fibrosis-affected sib pairs maps a paternally imprinted locus to 7q34.

Stanke F, Davenport C, Hedtfeld S, Tümmler B.

Eur J Hum Genet. 2010 May;18(5):553-9. doi: 10.1038/ejhg.2009.229. Epub 2010 Jan 6.

19.

Hierarchical fine mapping of the cystic fibrosis modifier locus on 19q13 identifies an association with two elements near the genes CEACAM3 and CEACAM6.

Stanke F, Becker T, Hedtfeld S, Tamm S, Wienker TF, Tümmler B.

Hum Genet. 2010 Apr;127(4):383-94. doi: 10.1007/s00439-009-0779-6. Epub 2010 Jan 3.

PMID:
20047061
20.

Genome diversity of Pseudomonas aeruginosa PAO1 laboratory strains.

Klockgether J, Munder A, Neugebauer J, Davenport CF, Stanke F, Larbig KD, Heeb S, Schöck U, Pohl TM, Wiehlmann L, Tümmler B.

J Bacteriol. 2010 Feb;192(4):1113-21. doi: 10.1128/JB.01515-09. Epub 2009 Dec 18.

21.

Characterization of the porcine transferrin gene (TF) and its association with disease severity following an experimental Actinobacillus pleuropneumoniae infection.

Daniłowicz E, Martinez-Arias R, Dolf G, Singh M, Probst I, Tümmler B, Höltig D, Waldmann KH, Gerlach GF, Stanke F, Leeb T; FUGATO-consortium IRAS.

Anim Genet. 2010 Aug;41(4):424-7. doi: 10.1111/j.1365-2052.2009.02012.x. Epub 2009 Dec 16.

PMID:
20015333
22.

Mutations in the amiloride-sensitive epithelial sodium channel in patients with cystic fibrosis-like disease.

Azad AK, Rauh R, Vermeulen F, Jaspers M, Korbmacher J, Boissier B, Bassinet L, Fichou Y, des Georges M, Stanke F, De Boeck K, Dupont L, Balascáková M, Hjelte L, Lebecque P, Radojkovic D, Castellani C, Schwartz M, Stuhrmann M, Schwarz M, Skalicka V, de Monestrol I, Girodon E, Férec C, Claustres M, Tümmler B, Cassiman JJ, Korbmacher C, Cuppens H.

Hum Mutat. 2009 Jul;30(7):1093-103. doi: 10.1002/humu.21011.

PMID:
19462466
23.

Transient correction of the basic defect in sweat glands in an individual with cystic fibrosis carrying the complex CFTR allele F508del-R553Q.

Tümmler B, Stanke F, Bronsveld I, Veeze H, Ballmann M.

Thorax. 2009 Feb;64(2):179-80. doi: 10.1136/thx.2008.096123.

PMID:
19176844
24.

Expression levels of FAS are regulated through an evolutionary conserved element in intron 2, which modulates cystic fibrosis disease severity.

Kumar V, Becker T, Jansen S, van Barneveld A, Boztug K, Wölfl S, Tümmler B, Stanke F.

Genes Immun. 2008 Dec;9(8):689-96. doi: 10.1038/gene.2008.63. Epub 2008 Aug 7.

PMID:
18685642
25.

Very mild disease phenotype of congenic CftrTgH(neoim)Hgu cystic fibrosis mice.

Tóth B, Wilke M, Stanke F, Dorsch M, Jansen S, Wedekind D, Charizopoulou N, Bot A, Burmester M, Leonhard-Marek S, de Jonge HR, Hedrich HJ, Breves G, Tümmler B.

BMC Genet. 2008 Apr 9;9:28. doi: 10.1186/1471-2156-9-28.

26.

Diversity of the basic defect of homozygous CFTR mutation genotypes in humans.

Stanke F, Ballmann M, Bronsveld I, Dörk T, Gallati S, Laabs U, Derichs N, Ritzka M, Posselt HG, Harms HK, Griese M, Blau H, Mastella G, Bijman J, Veeze H, Tümmler B.

J Med Genet. 2008 Jan;45(1):47-54. doi: 10.1136/jmg.2007.053561.

27.

CFTR protein analysis of splice site mutation 2789+5 G-A.

van Barneveld A, Stanke F, Claass A, Ballmann M, Tümmler B.

J Cyst Fibros. 2008 Mar;7(2):165-7. Epub 2007 Aug 16.

28.

Genetic variants of chemokine receptor CCR7 in patients with systemic lupus erythematosus, Sjogren's syndrome and systemic sclerosis.

Kahlmann D, Davalos-Misslitz AC, Ohl L, Stanke F, Witte T, Förster R.

BMC Genet. 2007 Jun 22;8:33.

29.

Transmission ratio distortion and maternal effects confound the analysis of modulators of cystic fibrosis disease severity on 19q13.

Becker T, Jansen S, Tamm S, Wienker TF, Tümmler B, Stanke F.

Eur J Hum Genet. 2007 Jul;15(7):774-8. Epub 2007 Apr 4.

30.

Cystic fibrosis disease-specific centiles in 2000 and 2005.

Stanke F, Ballmann M, Tümmler B.

Am J Respir Crit Care Med. 2006 May 1;173(9):1047; author reply 1047. No abstract available.

PMID:
16632637
31.

Spontaneous rescue from cystic fibrosis in a mouse model.

Charizopoulou N, Wilke M, Dorsch M, Bot A, Jorna H, Jansen S, Stanke F, Hedrich HJ, de Jonge HR, Tümmler B.

BMC Genet. 2006 Mar 29;7:18.

32.

Ex vivo biochemical analysis of CFTR in human rectal biopsies.

van Barneveld A, Stanke F, Ballmann M, Naim HY, Tümmler B.

Biochim Biophys Acta. 2006 Apr;1762(4):393-7. Epub 2006 Feb 13.

33.

The TNFalpha receptor TNFRSF1A and genes encoding the amiloride-sensitive sodium channel ENaC as modulators in cystic fibrosis.

Stanke F, Becker T, Cuppens H, Kumar V, Cassiman JJ, Jansen S, Radojkovic D, Siebert B, Yarden J, Ussery DW, Wienker TF, Tümmler B.

Hum Genet. 2006 Apr;119(3):331-43. Epub 2006 Feb 4.

PMID:
16463024
34.

Genetic modifiers in cystic fibrosis.

Stanke F, Tümmler B, Becker T.

N Engl J Med. 2006 Jan 5;354(1):88-90; author reply 88-90. No abstract available.

PMID:
16394309
35.

The CLCA gene locus as a modulator of the gastrointestinal basic defect in cystic fibrosis.

Ritzka M, Stanke F, Jansen S, Gruber AD, Pusch L, Woelfl S, Veeze HJ, Halley DJ, Tümmler B.

Hum Genet. 2004 Nov;115(6):483-91. Epub 2004 Oct 13.

PMID:
15490240
36.

Ex vivo CF diagnosis by intestinal current measurements (ICM) in small aperture, circulating Ussing chambers.

De Jonge HR, Ballmann M, Veeze H, Bronsveld I, Stanke F, Tümmler B, Sinaasappel M.

J Cyst Fibros. 2004 Aug;3 Suppl 2:159-63. Review.

37.

Basic protocol for transepithelial nasal potential difference measurements.

Schüler D, Sermet-Gaudelus I, Wilschanski M, Ballmann M, Dechaux M, Edelman A, Hug M, Leal T, Lebacq J, Lebecque P, Lenoir G, Stanke F, Wallemacq P, Tümmler B, Knowles MR.

J Cyst Fibros. 2004 Aug;3 Suppl 2:151-5. Review.

38.

Instability of the insertional mutation in CftrTgH(neoim)Hgu cystic fibrosis mouse model.

Charizopoulou N, Jansen S, Dorsch M, Stanke F, Dorin JR, Hedrich HJ, Tümmler B.

BMC Genet. 2004 Apr 21;5:6.

39.

[Endothelin-1 and cardiovascular diseases].

Cracowski JL, Stanke F, Bessard G.

Rev Med Interne. 1999 Jul;20(7):589-96. Review. French.

PMID:
10434349
40.

Effect of topical vasodilators on gastroepiploic artery graft.

Chavanon O, Cracowski JL, Hacini R, Stanke F, Durand M, Noirclerc M, Blin D.

Ann Thorac Surg. 1999 May;67(5):1295-8.

PMID:
10355400
41.

Frusemide inhibits angiotensin II-induced contraction on human vascular smooth muscle.

Stanke F, Devillier P, Bréant D, Chavanon O, Sessa C, Bricca G, Bessard G.

Br J Clin Pharmacol. 1998 Dec;46(6):571-5.

42.

Comparison between the reactivities of fresh, preserved at 4 degrees C and cryopreserved abdominal aortae of the rabbit.

Skowron O, Descotes JL, Stanke F, Baudot A, Riebel D, Bessard G, Egelhoffer H, Mazuer J, Odin J.

Transplant Proc. 1998 Sep;30(6):2847-8. No abstract available.

PMID:
9745591
43.

Functional assessment of human femoral arteries after cryopreservation.

Stanke F, Riebel D, Carmine S, Cracowski JL, Caron F, Magne JL, Egelhoffer H, Bessard G, Devillier P.

J Vasc Surg. 1998 Aug;28(2):273-83.

44.

Glibenclamide inhibits thromboxane A2-induced contraction in human internal mammary artery and saphenous vein.

Stanke F, Cracowski JL, Chavanon O, Magne JL, Blin D, Bessard G, Devillier P.

Eur J Pharmacol. 1998 Jan 2;341(1):65-71.

PMID:
9489857
45.

[Macrolides and drug interactions: review of the literature].

Lauby V, Mallaret M, Dufrêne I, Amalfitano G, Stanke F.

Therapie. 1996 Mar-Apr;51(2):177-84. Review. French.

PMID:
8763053
46.

Simultaneous determination of zolpidem and zopiclone in human plasma by gas chromatography-nitrogen-phosphorus detection.

Stanke F, Jourdil N, Bessard J, Bessard G.

J Chromatogr B Biomed Appl. 1996 Jan 12;675(1):43-51.

PMID:
8634767
47.

[Interactions between ergot derivatives and macrolides are still topical: ravages of self medication].

Juge S, Lauby V, Mallaret M, Musiedlak G, Stanke F, Bessard G.

Rev Med Interne. 1995;16(4):295. French. No abstract available.

PMID:
7746974
48.

[Reinforced glass ionomer restorations in modified Class II cavities].

Valenzuela V, Stanke F.

Odontol Chil. 1989 Apr;37(1):209-13. Spanish.

PMID:
2518367
49.

[Pins used in dental restoration].

Alday T, Stanke F, Venegas C.

Rev Chil Odontoestomatol. 1987 Jul;1(1):32-5. Spanish. No abstract available.

PMID:
3483056

Supplemental Content

Loading ...
Support Center